Frontage Holdings Corporation (HKG:1521)
1.030
-0.010 (-0.96%)
Jun 18, 2026, 11:52 AM HKT
Frontage Holdings Revenue
In the year 2025, Frontage Holdings had annual revenue of $256.69M USD with 0.70% growth. Frontage Holdings had revenue of $130.11M in the half year ending December 31, 2025, a decrease of -1.05%.
Revenue
$256.69M
Revenue Growth
+0.70%
P/S Ratio
1.06
Revenue / Employee
$168.54K
Employees
1,523
Market Cap
2.11B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 256.69M | 1.78M | 0.70% |
| Dec 31, 2024 | 254.91M | -4.95M | -1.90% |
| Dec 31, 2023 | 259.86M | 9.50M | 3.79% |
| Dec 31, 2022 | 250.36M | 65.92M | 35.74% |
| Dec 31, 2021 | 184.44M | 58.63M | 46.60% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Viva Biotech Holdings | 1.92B |
| AIM Vaccine | 1.30B |
| BioDlink International Company | 831.99M |
| Mabpharm | 718.98M |
| Antengene Corporation | 117.22M |
| SinoMab BioScience | 6.28M |
| Clover Biopharmaceuticals | 3.90M |
| TYK Medicines | 117.25K |